Physician profile
Adele A Thiel
NPI 1992810691
$9,715.56
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,855 · 2020: $1,323 · 2021: $2,667 · 2022: $2,479 · 2023: $1,307 · 2024: $84.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.26 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,045.16 | 2019-2023 | Austedo, Austedo Xr |
| Abbvie INC. | $643.51 | 2021-2024 | Qulipta, Botox |
| Genzyme Corporation | $582.43 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $538.75 | 2019-2023 | Nuplazid |
| Emd Serono, INC. | $454.55 | 2019-2023 | Mavenclad |
| Avanir Pharmaceuticals, INC. | $426.14 | 2019-2022 | |
| Eisai INC. | $370.52 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $355.24 | 2019-2023 | |
| Amgen INC. | $349.88 | 2019-2023 | Aimovig |
| Kyowa Kirin, INC. | $330.09 | 2019-2022 | |
| Acorda Therapeutics, INC | $327.85 | 2019-2023 | Inbrija |
| Genentech USA, INC. | $325.26 | 2019-2023 | Ocrevus |
| Allergan, INC. | $318.59 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $314.32 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $285.81 | 2020-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adele Thiel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.